Real‑world treatment outcomes among patients with metastatic pancreatic cancer in Japan : The Tokushukai real‑world data project
Copyright: © Shimoyama et al..
The present study aimed to investigate temporal trends in treatment patterns and prognostic factors for overall survival (OS) among patients with metastatic pancreatic cancer. From the Tokushukai REAl-world Data project, 1,093 patients with metastatic pancreatic cancer treated with gemcitabine, tegafur/gimeracil/oteracil (S-1), gemcitabine plus S-1, gemcitabine plus nab-paclitaxel, or fluorouracil, folic acid, oxaliplatin and irinotecan (FOLFIRINOX) between April 2010 and March 2020 were identified. Stratified/conventional Cox regression analyses were conducted to examine associations between patient- and tumor-related factors, study period, hospital volume, hospital type and first-line chemotherapy regimens. Overall, 846 patients were selected (503 male patients; median age, 70 years) after excluding ineligible patients. Over a median follow-up of 5.4 months, the median OS was 6.8 months (95% confidence interval, 6.3-7.4). The median OS for gemcitabine, S-1, gemcitabine plus S-1, gemcitabine plus nab-paclitaxel and FOLFIRINOX regimens was 5.9, 5.3, 7.7, 9.0 and 9.5 months, respectively. The median OS for 2010-2013, 2014-2017 and 2017-2020 was 6.2, 7.1 and 7.8 months, respectively. Performance status, body mass index and first-line chemotherapy regimens were identified to be significant prognostic factors. In summary, the real-world data indicated that standard care, including chemotherapy, for metastatic pancreatic cancer was widely used in hospitals throughout Japan and verified the survival benefits of gemcitabine plus nab-paclitaxel and FOLFIRINOX observed in prior clinical trials. This trial has been registered in the University Hospital Medical Information Network Clinical Trials Registry as UMIN000050590 on April 1, 2023.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Molecular and clinical oncology - 19(2023), 6 vom: 31. Dez., Seite 98 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shimoyama, Rai [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chemotherapy |
|---|
| Anmerkungen: |
Date Revised 22.11.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3892/mco.2023.2694 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364455136 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364455136 | ||
| 003 | DE-627 | ||
| 005 | 20231226095452.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3892/mco.2023.2694 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1214.xml |
| 035 | |a (DE-627)NLM364455136 | ||
| 035 | |a (NLM)37953858 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shimoyama, Rai |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real‑world treatment outcomes among patients with metastatic pancreatic cancer in Japan |b The Tokushukai real‑world data project |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright: © Shimoyama et al. | ||
| 520 | |a The present study aimed to investigate temporal trends in treatment patterns and prognostic factors for overall survival (OS) among patients with metastatic pancreatic cancer. From the Tokushukai REAl-world Data project, 1,093 patients with metastatic pancreatic cancer treated with gemcitabine, tegafur/gimeracil/oteracil (S-1), gemcitabine plus S-1, gemcitabine plus nab-paclitaxel, or fluorouracil, folic acid, oxaliplatin and irinotecan (FOLFIRINOX) between April 2010 and March 2020 were identified. Stratified/conventional Cox regression analyses were conducted to examine associations between patient- and tumor-related factors, study period, hospital volume, hospital type and first-line chemotherapy regimens. Overall, 846 patients were selected (503 male patients; median age, 70 years) after excluding ineligible patients. Over a median follow-up of 5.4 months, the median OS was 6.8 months (95% confidence interval, 6.3-7.4). The median OS for gemcitabine, S-1, gemcitabine plus S-1, gemcitabine plus nab-paclitaxel and FOLFIRINOX regimens was 5.9, 5.3, 7.7, 9.0 and 9.5 months, respectively. The median OS for 2010-2013, 2014-2017 and 2017-2020 was 6.2, 7.1 and 7.8 months, respectively. Performance status, body mass index and first-line chemotherapy regimens were identified to be significant prognostic factors. In summary, the real-world data indicated that standard care, including chemotherapy, for metastatic pancreatic cancer was widely used in hospitals throughout Japan and verified the survival benefits of gemcitabine plus nab-paclitaxel and FOLFIRINOX observed in prior clinical trials. This trial has been registered in the University Hospital Medical Information Network Clinical Trials Registry as UMIN000050590 on April 1, 2023 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a FOLFIRINOX | |
| 650 | 4 | |a RWD | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a gemcitabine plus nab-paclitaxel | |
| 650 | 4 | |a metastatic pancreatic cancer | |
| 700 | 1 | |a Imamura, Yoshinori |e verfasserin |4 aut | |
| 700 | 1 | |a Uryu, Kiyoaki |e verfasserin |4 aut | |
| 700 | 1 | |a Mase, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Fujimura, Yoshiaki |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashi, Maki |e verfasserin |4 aut | |
| 700 | 1 | |a Ohtaki, Megu |e verfasserin |4 aut | |
| 700 | 1 | |a Ohtani, Keiko |e verfasserin |4 aut | |
| 700 | 1 | |a Shinozaki, Nobuaki |e verfasserin |4 aut | |
| 700 | 1 | |a Minami, Hironobu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular and clinical oncology |d 2013 |g 19(2023), 6 vom: 31. Dez., Seite 98 |w (DE-627)NLM236574981 |x 2049-9469 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:6 |g day:31 |g month:12 |g pages:98 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3892/mco.2023.2694 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 6 |b 31 |c 12 |h 98 | ||